CRISPR Therapeutics Analyst Ratings
Ionis Pharmaceuticals Will Present New Three-year Data From The Phase 2 Open-label Extension Study As Well As Additional Results From The Pivotal Phase 3 OASIS and OASISplus Studies Of Donidalorsen For Hereditary Angioedema At The 2024 American...
Adaptive Biotechnologies Analyst Ratings
Veracyte Presents New Data Findings Are From The Prospective, Multicenter VANDAAM Trial, Show That Its Decipher Prostate Test Predicts Aggressive Prostate Cancer In African American Men At ASTRO 2024
Unveiling 3 Analyst Insights On Arcturus Therapeutics
Twist Bioscience Analyst Ratings
10x Genomics Short Call Reiterated at Hedgeye, Sees Potential for 50% Downside
Jabil Posts Upbeat Earnings, Joins Micron Technology, Southwest Airlines And Other Big Stocks Moving Higher On Thursday
12 Health Care Stocks Moving In Thursday's Intraday Session
Crude Oil Down Over 2%; US Initial Jobless Claims Fall
Ionis Pharmaceuticals Analyst Ratings
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
Health Canada Approves CASGEVY (Exagamglogene Autotemcel), The First CRISPR/Cas9 Gene-Edited Therapy, For Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia In Patients 12 And Older
Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
Jones Trading Initiates Coverage On Intellia Therapeutics With Buy Rating, Announces Price Target of $41
Intellia Therapeutics Analyst Ratings
Reported Earlier Intellia Therapeutics To Present Data From The Phase 2 Study Of NTLA-2002 For The Treatment Of Hereditary Angioedema At The 2024 ACAAI Annual Scientific Meeting; To Host Investor Webcast On October 28, At 8:00 A.m. ET
Small-cap Stocks Have Climbed Recently. Here Are the Ones Most Poised for Further Upside
Looking Into Recursion Pharmaceuticals's Recent Short Interest
Coeur Mining, Medical Properties Trust And RH Are Among Top 7 Mid Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?